



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.									
				FILING DATE: December 29, 2003		GROUP: 1614							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA												
	BB												
	BC												
	BD												
	BE												
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	BF												
	BG												
	BH												
	BI												
	BJ												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	BK												
	BL												
	BN												
	BO												
	BP												
	BQ												
	BR	Miakowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 30:263-274.											
EXAMINER									DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	DH						
	DI						
	DJ						
	DK						
	DL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	DM	Alvarez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Ora Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.					
	DN	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52:659-663.					
	DO	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone Research Monograph 28 (1980) p. 3-9.					
	DP	Baum et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 p. 426-429.					
	DQ	Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 55-83.					
	DR	Bloom et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 th National Conference on Methadone Treatment (1973) Vol 2, p. 1342-1349.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						
	ED						
	EE						
	EF						
	EG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	EH						
	EI						
	EJ						
	EK						
	EL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	EM	Briscoe et al., "Methodocinnamox: Time Course of Changes in Alfenanil-Reinforced Rhesus Monkeys"; Psychopharmacology (2000) 148:393-399.					
	EN	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) p. 545-551.					
	EO	Bullingham et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm (1983) 8: 332-343.					
	EP	Calimlim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and There (1974) Vol. 15; No. 6 pp.556-564.					
	EQ	Caruso et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment if Heroin Addicts"; Bristol Laboratories, pp.1336-1341F.					
	ER	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May:51 (5) pp. 713-737.					
	ES	Chiang, et al. "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pp.1-8.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
	FB						
	FC						
	FD						
	FE						
	FF						
	FG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	FH						
	FI						
	FJ						
	FK						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	FL	Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin Pharmacol Thera (1984) Vol 36 No. 5, pp.704-708.					
	FM	Comer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects Of Heroin un Humans"; Psychopharmacology (2002) 159, pp.351-360.					
	FN	Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist"; Clinical Pharmacy, Vol. 3 (1984) pp.273-280.					
	FO	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999)pp.1-11.					
	FP	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp.121-131.					
	FQ	Fink et al., "naloxone in Heroin Dependence"; Clin Pharm and Thera. Vol 9, No. 5;pp.568-577.					
	FR	Fishman et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic Dependent Men"; J. Pharm. And Exper. Thera (1973)Vol 10 No. 2;pp.575-580.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
	GD						
	GE						
	GF						
	GG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	GH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	GI	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I (1990) Vol 10, No. 2; pp.375-386.					
	GJ	Freye et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary light Reflex"; Arzneim-Forsch/Drug Res. 50(I)(2000)pp. 24-30.					
	GK	Fudala, et al., "Effects of Buprenorphine asnd Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8.					
	GL	Fudala et al., "Human Pharmacology and Abuse Potential Of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pp. 300-306.					
	GM	Gal et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 537-542.					
	GN	Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pp. 35-41.					
	GO	Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
	HB						
	HC						
	HD						
	HE						
	HF						
	HG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	HH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	HI	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol.17, No.3, pp. 193-197					
	HJ	Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, pp. 1639-1647.					
	HK	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting μ Opioids in Drug Abusers"; J. Pharm and Exper Thera (1996) Vol 277, No 3, pp. 1228-1236.					
	HL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol 29, pp. 33-39.					
	HM	Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II)(1985)pp. 1742-1744.					
	HN	Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pp. 173-176.					
	HO	Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) Vol 307, pp. 251-257.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
	IB						
	IC						
	ID						
	IE						
	IF						
	IG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	IH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	IJ	Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846.					
	IK	Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174.					
	IL	Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211.					
	IM	Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458.					
	IN	Stine et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209.					
	IO	Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242.					
	IP	Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993.					
	IQ	Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383.					
	IR	Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634.					
	IS	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.							
				FILING DATE: December 29, 2003		GROUP: 1614					
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	JA										
	JB										
	JC										
	JD										
	JE										
	JF										
	JG										
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO
	JH										
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
	JI	Umbricht et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56 pp. 181-190									
	JK	Vaccarino et al., "Enogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034.									
	JL	Wang et al., "Inverse Agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) Vol 77, pp. 1590-1600.									
	JM	Way et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261.									
	JN	Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) Vol 44, No 3, pp. 335-342.									
	JO	Wells, et al., "In vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid μ -Agonist/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper Thera (2001) Vol 297, No 2, pp. 597-605									
	JP	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pp. 4-6.									
	JQ	Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pp. 139-148.									
	JR	Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration if NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pp. 325-336.									
EXAMINER							DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
	KB						
	KC						
	KD						
	KE						
	KF						
	KG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	KH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	KI	Han et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) Vol 177, pp. 201-209.					
	KJ	Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pp. 438-445.					
	KK	Harris et al., "Buprenorphine and Naloxone co-administration in opiate dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pp. 85-94.					
	KL	Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pp. 625-630.					
	KM	Högger et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) Vol 37, No 8, pp. 377-385					
	KN	Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011.					
	KO	Crain et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence					
	KP	Howes et al., "The Pharmacology of TR5109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105.					
	KQ	Leeling et al., "Disposition and metabolism of codorphone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp 649-653.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	LH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	LI	Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152.					
	LJ	Hassain et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130.					
	LK	Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) Vol 157, No 2, pp. 420-426.					
	LM	Jones et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusers in humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37.					
	LN	Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (1992) Vol 260, No. 1, pp. 355-363.					
	LO	King et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exper Res (1997) Vol 21, No 5, pp. 906-909.					
	LP	Kogan et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. In Chem. Path. And Pharm (1977) Vol 18, No. 1, pp 29-34.					
	LQ	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J of Psychiatry (1994) Vol 1, p 151.					
	LR	Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, OO. 73-78.					
	LS	Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No 5, pp. 663-672.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						
	MB						
	MC						
	MD						
	ME						
	MF						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	MG						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	MH	Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pp.810-815					
	MI	Lehman, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) Vol 34, pp. 343-352.					
	MJ	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pp. 1574-1577.					
	MK	Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pp. 157-160.					
	ML	Martin et al. "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneimittel-Forsch./Drug Res. (1999) Vol 49, pp. 599-607.					
	MM	Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. Of Pharm and Exper Thera (1965) Vol 150, No 3. Pp. 437-442.					
	MN	Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pp. 37-46.					
	MO	Mendelson et al., "Buprenorphine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pp. 1095-1101.					
	MP	Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. Vol 15, No 2., pp 156-166					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.										
				FILING DATE: December 29, 2003		GROUP: 1614								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	NA													
	NB													
	NC													
	ND													
	NE													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
	NF													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	NG	Parwatar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Thera, Vol 14, No. 6, pp 941-948.												
	NH	Parwatar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354.												
	NI	Pitts et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271, No 3, pp. 1501-1508.												
	NJ	Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), Vol 94, pp. 484-490.												
	NK	Preston et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Exper Thera (1993) Vol 264, No 2 pp. 813-823.												
	NL	Preston et al., "Effects of Sublingually given naloxone in Opioid -dependant human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pp. 27-34.												
	NM	Bigelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149.												
	NN	Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts)"; N-Allylnormorphine During Narcoctic Addiction (1953) pp. 8-20.												
EXAMINER									DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT(S): Benjamin OSHLACK et al.						
					FILING DATE: December 29, 2003		GROUP: 1614				
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	OA										
	OB										
	OC										
	OD										
	OE										
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO
	OF										
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)											
	OG	Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No 13, pp. 2108-2110.									
	OH	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No 1, pp. 54-58.									
	OI	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213.									
	OJ	Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thera (1995) Vol 33, No 9, 524-529.									
	OK	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258.									
	OL	Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526.									
	OM	Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No 2, pp. 206-217.									
	ON	Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol 28, pp. 49-82.									
	OO	Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim-Forsch/Drug Res. (2000) Vol 50, pp. 1015-1022.									
EXAMINER							DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	RA						
	RB						
	RC						
	RD						
	RE						
	RF						
	RG						
	RH						
	RI						
	RJ						
	RK						
	RL						
	RM						
	RN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	RO						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	RP						
	RQ	Physician's Desk Reference (2001) see Revia, pp. 1146-1149 and Oxycontin, pp. 2697-2701					
	RR						
	RS						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.										
				FILING DATE: December 29, 2003		GROUP: 1614								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
													YES	NO
JR	BA	3	9	1	6	8	8	9	11/04/1975	Russell	128	145.8		
JR	BB	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22		
JR	BC	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260		
JR	BD	4	1	7	6	1	8	6	11/79	Goldberg	424	260		
JR	BE	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JR	BF	9	7	3	3	5	6	6	9/97	WO	A61K	9/20		
JR	BG	9	8	3	5	6	7	9	8/98	WO	A61K	31/485		
JR	BH	9	9	3	2	1	2	0	7/99	WO	A61K	31/485		
JR	BI	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00		
JR	BJ	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
JR	BK	Chih-Cheng Chien, et al., "Sigma Antagonists Potentiate Opioid Analgesia in Rats", Neuroscience Letters 190 (1995), 137-139.												
JR	BL	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995) 92:10540-10544.												
JR	BN	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.												
JR	BO	Tatwin NX, Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ 2120-2121.												
JR	BP	Foss et al., "Dose related Antagonism of the Emetic Effect of Morphine by Methylnaltrexone in Dogs", J. Clin Pharmacol (1993), 33:747-751												
JR	BQ	Holmes et al., "Inhibiting Spinal Dynorphin A Component Enhances Intrathecal Morphine Antinociception in Mice", Anesth. Analg. (1993), 77:1166-73.												
JR	BR	Mikowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 50:263-274.												
EXAMINER Jeffrey E. Russell										DATE CONSIDERED January 25, 2005				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

BEST AVAILABLE COPY

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10747,865								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.										
				FILING DATE: December 29, 2003		GROUP: 1614								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		DA	4	5	7	3	9	9					5	YES
<i>BL</i>	DA	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
<i>BL</i>	DB	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
<i>BL</i>	DC	4	6	0	8	3	7	6	8/86	Pasternak	514	282		
<i>BL</i>	DD	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282		
<i>BL</i>	DE	4	7	1	9	2	1	5	1/88	Goldberg	514	282		
<i>BL</i>	DF	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45		
<i>BL</i>	DG	4	7	6	0	0	6	9	7/88	Rzeszutarski et al.	514	282		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO											
<i>BL</i>	DH	0	1	9	3	8	5	2	12/31/2001	WO (A2)	A61K	31/00		
<i>BL</i>	DI	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		
<i>BL</i>	DJ	0	6	4	7	4	4	8	4/95	EP	A61K	31/485		
<i>BL</i>	DK	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
<i>BL</i>	DL	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>BL</i>	DM	Alvarez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.												
<i>BL</i>	DN	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52:659-663.												
<i>BL</i>	DO	Archer, Sydney, "Historical Perspective on the Chemistry and Development of Naltrexone", Naltrexone Research Monograph 28 (1980) p. 3-9												
<i>BL</i>	DP	Baum et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4, p. 426-429.												
<i>BL</i>	DQ	Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 53-83.												
<i>BL</i>	DR	Bloom et al., "Clinical Studies with Naloxone/Metadone in a Ratio of 1:20"; 5th National Conference on Methadone Treatment (1973) Vol 2, p. 1342-1349.												
EXAMINER <i>Jeffrey E. Rosol</i>										DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	EA	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282	
JR	EB	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282	
JR	EC	4	8	0	3	2	0	8	2/89	Pasternak	514	282	
JR	ED	4	8	0	6	3	4	1	2/89	Chien et al.	424	448	
JR	EE	4	8	0	6	5	4	3	2/89	Choi	514	464	
JR	EF	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381	
JR	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JR	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
JR	EI	0	3	1	9	2	4	3	06/07/1989	EP (A1)	A61K	31/485		
JR	EJ	0	3	1	9	2	4	3	11/07/1990	EP (B1)	A61K	31/485		
JR	EK	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		
JR	EL	29	7	1	9	7	0	4	2/97	DE	A61K	31/485	x	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	EM	Briscoe et al., "Methoclopramide: Time Course of Changes in Aflerant-Reinforced Rhesus Monkeys", Psychopharmacology (2000) 148:393-399.
✓	EN	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man", Meth and Find Exp Clin Pharmacol 5 (8) (1983) p. 545-551.
✓	EO	Bullingham et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs", Clinical Pharm (1983) 8: 332-343.
✓	EP	Calimim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination", Clin Pharmacol and Ther (1974) Vol. 15; No. 6 pp.556-564.
✓	EQ	Caruso et al., "Methadone and Naloxone in Combination (Naloxone) for the Treatment of Heroin Addicts", Bristol Laboratories, pp.1336-1341F.
✓	ER	Cherny, Nathan I., "Opioid Analgesics", Drugs (1996) May;51 (5) pp. 713-797.
✓	ES	Chiang, et al. "Clinical Evaluation of a Naloxone Sustained-Release Preparation", Drug and Alcohol Dependence (1985) 16, pp.1-8.

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10747,865								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.										
				FILING DATE: December 29, 2003		GROUP: 1614								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	FA	FB	FC	FD	FE	FF	FG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JA								4 8 3 4 9 6 5	05/30/1989	Martani et al.	424	488		
JA								4 8 3 4 9 8 4	05/30/1989	Goldie et al.	424	488		
JA								4 8 3 4 9 8 5	05/30/1989	Elger et al.	424	488		
JA								4 8 4 4 9 0 7	07/04/1989	Elger et al.	424	465		
JA								4 8 4 4 9 0 9	07/04/1989	Goldie et al.	424	480		
JA								4 8 4 4 9 1 0	07/04/1989	Leslie et al.	424	494		
JA								4 8 6 1 5 9 8	8/89	Oshlak et al.	424	468		
								FOREIGN PATENT DOCUMENTS						
													TRANSLATION	
													YES	NO
JA								4 3 2 5 4 6 5	2/95	DE	A61K	31/485		x
JA								2 2 2 2 0 3 9	11/72	DE	A61K	27/00		
JA								9 8 2 5 6 1 3	06/18/98	WO	A61K	31/485	abstract	
JA								0 0 3 8 6 4 9	07/06/00	WO	A61K	9/00	abstract	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
FL	Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation", Clin Pharmacol Ther (1984) Vol 36 No. 5, pp.704-708.													
FM	Gomer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects Of Heroin in Humans", Psychopharmacology (2002) 159, pp.354-360.													
FN	Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist", Clinical Pharmacy, Vol. 3 (1984) pp.273-280.													
FO	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability", Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999) pp.1-11.													
FP	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability", Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp.121-131.													
FQ	Fink et al., "naltrexone in Heroin Dependence", Clin Pharm and Thera. Vol 9, No. 5, pp.568-577.													
FR	Fishman et al., "Disposition of Naltrexone-7,8- ³ H in Normal & Narcotic Dependent Men", J. Pharm. And Exper. Thera (1973) Vol 10 No. 2, pp.575-588.													
EXAMINER: <u>Jeffrey E. Russe</u>										DATE CONSIDERED: <u>January 25, 2005</u>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

BEST AVAILABLE COPY

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JR	GA 4 8 6 1 7 8 1	8/89	Goldberg	514	282		
JR	GB 4 8 6 7 9 8 5	09/19/1989	Heafield et al.	424	461		
JR	GC 4 8 7 3 0 7 6	10/89	Fishman et al.	412	10		
JR	GD 4 8 8 2 3 3 5	11/89	Sinclair	514	282		
JR	GE 4 8 8 9 8 6 0	12/89	Rzeszotarski et al.	514	282		
JR	GF 4 9 3 5 4 2 8	6/90	Lewis	514	282		
JR	GG 4 9 4 0 5 8 7	07/10/1990	Jenkins et al.	424	480		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JR	CH 00 1 5 8 4 7 7	8/16/01	WO	A61P		abstract	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
/	GI	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1 (1990) Vol 10, No. 2; pp.375-386.					
/	GJ	Freye et al., "Effects of Tramadol and Tildine/Naloxone on Oral-Caecal Transit & Pupillary light Reflex"; Arzneim-Forsch/Drug Res. 50(1)(2000) pp. 24-30.					
/	GK	Fudala, et al., "Effects of Buprenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8.					
/	GL	Fudala et al., "Human Pharmacology and Abuse Potential Of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pp. 300-306.					
/	GM	Gai et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 637-642.					
/	GN	Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pp. 35-41.					
/	GO	Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113.					
EXAMINER Jeffrey E. Russell			DATE CONSIDERED January 25, 2005				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10/747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JN	HA	4	2	0	0	0	9	8	04/29/1980	Ayer, et al.	128	260	
JN	HB	4	9	7	0	0	7	5	11/13/1990	Oshlak	424	451	
JN	HC	4	9	8	7	1	3	6	01/22/1991	Kreek et al.	514	282	
JN	HD	4	9	9	0	3	4	1	02/05/1991	Goldie et al.	424	484	
JN	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497	
JN	HF	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282	
JN	HG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JN	HH	00	1	8	5	1	5	0	11/15/01	WO	A61K	31/00		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	HI	Chau, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol. 17, No. 3, pp. 193-197
✓	HJ	Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) Vol. 91, No. 6, pp. 1639-1647.
✓	HK	Greenwald, et al. "Comparative Clinical Pharmacology of Short Acting μ -Opioids in Drug Abusers"; J. Pharm and Exper Thera (1996) Vol 277, No 3, pp. 1228-1236.
✓	HL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol. 29, pp. 33-39.
✓	HM	Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drugs Res. 35 (No II)(1985)pp. 1742-1744.
✓	HN	Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pp. 173-176.
✓	HO	Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) Vol 307, pp. 251-257.

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.										
				FILING DATE: December 29, 2003		GROUP: 1614								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JR	IA	5	0	9	1	1	8	9	02/25/1992	Heafield et al.	424	457		
JR	IB	5	0	9	6	7	1	5	3/92	Sinclair	424	449		
JR	IC	5	1	0	2	8	8	7	4/92	Goldberg	514	282		
JR	ID	4	1	6	0	0	2	0	07/03/1979	Ayer, et al.	424	15		
JR	IE	5	1	4	9	5	3	8	9/92	Granger et al.	424	449		
JR	IF	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488		
JR	IG	5	2	2	5	4	4	0	7/93	London et al.	514	535		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
JR	IH	00	0	6	7	7	3	9	11/16/00	WO	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
U	✓	Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846.												
IK	✓	Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174.												
IL	✓	Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211.												
IM	✓	Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458.												
IN	✓	Stine et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. Clinical Psych (1992) Vol 12, No 3, pp. 203-209.												
IO	✓	Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242.												
IP	✓	Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993.												
IQ	✓	Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383.												
IR	✓	Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634.												
IS	✓	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages												
EXAMINER <i>Jeffrey E. Russel</i>										DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

BEST AVAILABLE COPY

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10/747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JN	JA	5	2	2	6	3	3	1	07/13/1993	Thompson et al.	73	865.9	
JN	JB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449	
JN	JC	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282	
JN	JD	5	2	6	6	3	3	1	11/30/1993	Oshlak et al.	424	468	
JN	JE	5	2	7	3	7	6	0	12/93	Oshlak et al.	424	486	
JN	JF	5	2	8	6	4	9	3	02/15/1994	Oshlak et al.	424	468	
JN	JG	5	3	1	6	7	5	9	12/93	Rose et al.	424	10	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JN	JH	00	0	5	1	5	9	2	9/05/00	WO	A61K	31/14		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JL	✓	Wang et al., "Inverse Agonists and neutral antagonists at μ -opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) Vol 77, pp. 1590-1600.
JK	✓	Vaccarino et al., "Enogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034.
JM	✓	Wey et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261.
JN	✓	Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) Vol 44, No 3, pp. 335-342.
JO	✓	Wells, et al., "In vivo Pharmacological Characterization of SBRI 9409, a Nonpeptidic Opioid μ -Agonist/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper Thera (2001) Vol 297, No 2, pp. 597-605.
JP	✓	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pp. 4-6.
JO	✓	Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pp. 139-148.
JR	✓	Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pp. 325-336.

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JR	KA 5 3 1 7 0 2 2	5/94	Borsodi et al.	514	282		
JR	KB 5 3 2 1 0 1 2	6/94	Mayer et al.	514	25		
JR	KC 5 3 2 4 3 5 1	06/28/1994	Oshlak et al.	106	153		
JR	KD 5 3 3 6 6 9 1	08/09/1994	Raffa et al.	514	629		
JR	KE 5 3 5 2 6 8 0	10/94	Portoghese et al.	514	279		
JR	KF 5 3 5 2 6 8 3	10/94	Mayer et al.	514	289		
JR	KG 5 3 5 6 4 6 7	10/18/1994	Oshlak et al.	106	153		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JR	KH 0 1 5 8 4 5 1	08/19/2001	WO (A1)	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
KI	Han et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) Vol 177, pp. 201-209.						
KJ	Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pp. 438-445						
KK	Harris et al., "Buprenorphine and Naloxone co-administration in opiate dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pp. 85-94.						
KL	Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pp. 625-630.						
KM	Högger et al., "Comparison of tilidine/naloxone, tramadol and buprenorphine in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) Vol 37, No 8, pp. 377-385						
KN	Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011.						
KO	Grain et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence						
KP	Hoyes et al., "The Pharmacology of TR5109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105.						
KQ	Leeling et al., "Disposition and metabolism of codephone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp 649-653.						
EXAMINER Jeffrey E. Russel				DATE CONSIDERED January 25, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT(S): Benjamin OSHLACK et al.				
					FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
JR	LA	5 3 5 6 9 0 0	10/94	Bihari et al.	514	282			
JR	LB	5 3 7 6 6 6 2	12/94	Ockert	514	282			
JR	LC	3 5 4 1 0 0 5	11/17/1970	Strathmann, et al.	210	19			
JR	LD	5 4 1 1 7 4 5	05/02/1995	Oshlack et al.	424	456			
JR	LE	5 4 2 6 1 1 2	06/95	Zagon et al.	514	282			
JR	LF	3 5 4 1 0 0 6	11/17/1970	Bixler, et al.	210	23			
JR	LG	5 4 5 7 2 0 8	10/95	Portoghese et al.	546	35			
FOREIGN PATENT DOCUMENTS									
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
						YES	NO		
JR	LH	0 8 8 0 3 5 2	02/03/1998	EP (B1)	A61K	31/485	x		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
/	LI	Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152.							
/	LJ	Hassain et al., "Duccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130.							
/	LK	Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) Vol 157, No 2, pp. 420-426.							
/	LM	Jones et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusers in humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37.							
/	LN	Kannof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (1992) Vol 260, No. 1, pp. 355-363.							
/	LO	King et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exper Res (1997) Vol 21, No 5, pp. 906-909.							
/	LP	Kogen et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. In Chem. Path. And Pharm (1977) Vol 18, No. 1, pp 29-34.							
/	LQ	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J of Psychiatry (1994) Vol 1, p 151.							
/	LR	Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, OO. 73-78.							
/	LS	Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No 5, pp. 663-672.							
EXAMINER <i>Jeffrey E. Russel</i>			DATE CONSIDERED <i>January 25, 2005</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10/747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	MA	5	4	6	0	8	2	6	10/24/1995	Merrill et al.	424	470	
JR	MB	5	4	7	2	7	1	2	12/05/1995	Oshlack et al.	424	480	
JR	MC	5	4	7	2	9	4	3	12/95	Crain et al.	514	12	
JR	MD	5	4	7	8	5	7	7	12/26/1995	Sackler et al.	424	489	
JR	ME	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426	
JR	MF	5	5	0	0	2	2	7	03/19/1996	Oshlack et al.	424	476	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	MG													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MH	Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pp.810-815
MI	Lehman, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) Vol 34, pp. 343-352.
JR	MJ Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pp. 1574-1577.
ME	Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pp. 157-160.
ML	Martin et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneimittel-Forsch/Drug Res. (1999) Vol 49, pp. 599-607.
MM	Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. Of Pharm and Exper Thera (1965) Vol 150, No 3. Pp. 437-442.
MN	Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pp. 37-46.
MO	Mendelson et al., "Buprenorphine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pp. 1095-1101.
MP	Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. Vol 15, No 2, pp 156-166

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10/747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	NA	5	5	0	2	0	5	8		3/96	Mayer et al.	514	289	
JR	NB	5	5	0	8	0	4	2		04/16/1996	Oshlack et al.	424	468	
JR	NC	5	5	0	8	0	4	3		04/16/1996	Krishnamurthy	424	484	
JR	ND	5	5	1	2	5	7	8		4/96	Crain et al.	514	282	
JR	NE	5	5	1	4	6	8	0		5/96	Weber et al.	514	249	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	NF														

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NG	✓	Parwatikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts", Clin. Pharm and Ther., Vol 14, No. 6, pp 941-948.
NH	✓	Parwatikar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354.
NI	✓	Pitts et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271, No 3, pp. 1501-1508.
NJ	✓	Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), Vol 94, pp. 484-490.
NK	✓	Preston et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Exper Thera (1993) Vol 264, No 2 pp. 813-823.
NL	✓	Preston et al., "Effects of Sublingually given naloxone in Opioid-dependant human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pp. 27-34.
NM	✓	Digelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149.
NN	✓	Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts)"; N-Allylnormorphine During Narcotic Addiction (1953) pp. 8-20.

EXAMINER

Jeffrey E. Russe

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1134CONSERIAL NO.:
10747,865

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
December 29, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	OA	5	5	3	4	4	9	2	7/96	Aston et al.	514	608	
JR	OB	5	5	4	9	9	1	2	08/27/1996	Oshlack et al.	424	468	
JR	OC	5	5	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368	
JR	OD	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25	
JR	OE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	OF													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

- OG ☒ Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No 13, pp. 2108-2110.
- OH ☒ Barton et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No 1, pp. 54-58.
- OI ☒ Blachy, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213.
- OJ ☒ Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thera (1995) Vol 33, No 9, 524-529.
- OK ☒ Jasinski, D.R., "Assessment of the Abuse Potential of Morphine-like Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258.
- OL ☒ Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526.
- OM ☒ Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No 2, pp. 206-217.
- ON ☒ Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol 28, pp. 49-82.
- OO ☒ Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arznei-Forsch/Drug Res. (2000) Vol 50, pp. 1015-1022.

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

January 25, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10747,865														
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.																
				FILING DATE: December 29, 2003		GROUP: 1614														
U.S. PATENT DOCUMENTS																				
*EXAMINER INITIAL	RA	RB	RC	RD	RE	RF	RG	RH	RI	RJ	RK	RL	RM	RN	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JA															5 6 5 6 2 9 5	08/12/1997	Oshalck et al.	424	468	
JA															5 6 7 0 1 7 2	09/23/1997	Buxton et al.	424	495	
JA															5 6 7 2 3 6 0	09/30/1997	Sackler et al.	424	490	
JA															5 6 8 1 5 8 5	10/28/1997	Oshlack et al.	424	494	
JA															5 7 6 3 4 5 2	06/09/1998	Miller et al.	514	282	
JA															5 7 6 7 1 2 5	06/98	Crain et al.	514	282	
JA															5 7 8 0 4 7 9	07/14/1998	Kim	514	282	
JA															5 7 6 7 1 2 5	06/16/1988	Crain, et al.	514	282	
JA															6 0 9 6 7 5 6	08/01/2000	Crain, et al.	514	282	
JA															6 1 9 4 3 8 2	02/27/01	Crain, et al.	514	2	
JA															6 3 6 2 1 9 4	03/26/2002	Crain, et al.	514	285	
JA															6 3 9 5 7 0 5	05/28/2002	Crain, et al.	514	2	
JA															20 01 00 06 9 6 7	07/05/2001	Crain, et al.	514	253.04	
JA															20 01 00 18 4 1 3	08/30/2001	Crain, et al.	514	2	
FOREIGN PATENT DOCUMENTS																				
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
														YES	NO					
	RO																			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)																				
JA	RP	Ciccocioppo et al., "Effect of Nociceptin/orphanin FQ on the Rewarding Properties of Morphine"; Eur. J Pharmacol (2000) Vol 404, pp. 153-159.																		
	RQ	Physician's Desk Reference (2001) see Revia pp. 1146-1149 and Oxycontin, pp. 2697-2701																		
	RR																			
	RS																			
EXAMINER										DATE CONSIDERED										
Jeffrey E. Russell										January 25, 2005										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																				

BEST AVAILABLE COPY